Actively Recruiting
Randomized Study of Nalbuphine Extended-Release Tablets to Treat Chronic Cough in Idiopathic Pulmonary Fibrosis
Led by Trevi Therapeutics · Updated on 2026-10-13
306
Participants Needed
22
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of Nalbuphine Extended-Release NAL ER tablets in treating chronic cough in people with Idiopathic Pulmonary Fibrosis IPF. This phase 3 study aims to understand how NAL ER affects cough frequency and severity compared to a placebo. The study is led by Trevi Therapeutics and focuses on participants aged 40 and older who have persistent cough due to IPF. Participants will be randomly assigned to one of two groups. One group will take NAL ER tablets while the other receives matching placebo tablets. There will be a 2-week blinded titration period with once daily dosing followed by a 52-week fixed dose period with twice daily dosing. This design helps compare the effects of NAL ER versus placebo over a year-long treatment. During the trial, participants will be monitored regularly to track changes in cough frequency and severity using several scales and questionnaires, including the Cough Severity Numerical Rating Scale and the Leicester Cough Questionnaire. Safety and tolerability will also be assessed by recording adverse events. The main outcome measure is the relative change in 24-hour cough frequency after 26 weeks of treatment, with additional assessments continuing through 54 weeks. The total study duration for each participant is about one year.
CONDITIONS
Brief Title
Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) Tablets
Research Team
P
Paula Buckley
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here